MDGL · Madrigal Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| BAKER BROS. ADVISORS LP Director | ▲ Buy | Grant | 1,948,876 Shares held | 6/17/2026 | View profile |
| Rebecca Taub Pres., R&D, and CMO | ▲ Buy | Grant | 452,667 Shares held | 6/17/2026 | View profile |
| CRAVES FRED B Director | ▼ Sell | Open Market | 350,076 Shares held | 3/13/2025 | View profile |
| William John Sibold President and CEO | ▼ Sell | Open Market | 197,746 Shares held | 9/11/2026 | View profile |
| Paul A. Friedman Chief Executive Officer | ▼ Sell | Open Market | 187,164 Shares held | 1/9/2026 | View profile |
| Richard S. Levy Director | ▲ Buy | Grant | 22,469 Shares held | 6/17/2026 | View profile |
| Howarth Alex G. Chief Financial Officer | ▲ Buy | Grant | 18,737 Shares held | 1/23/2024 | View profile |
| Lynch Brian Joseph SVP and General Counsel | ▲ Buy | Grant | 17,691 Shares held | 1/23/2024 | View profile |
| Sukhija Remy Chief Commercial Officer | ▲ Buy | Grant | 15,001 Shares held | 1/16/2023 | View profile |
| Carole Huntsman Chief Commercial Officer | ▼ Sell | Open Market | 12,692 Shares held | 3/6/2026 | View profile |
| Mardi Dier CFO & Executive Vice President | ▼ Sell | Open Market | 12,490 Shares held | 3/6/2026 | View profile |
| Shannon T. Kelley General Counsel | ▼ Sell | Open Market | 11,474 Shares held | 8/17/2026 | View profile |
| David Soergel Chief Medical Officer | ▼ Sell | Open Market | 10,033 Shares held | 6/1/2026 | View profile |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | ▲ Buy | Grant | 5,789 Shares held | 3/5/2025 | View profile |
| James M. Daly Director | ▲ Buy | Grant | 3,081 Shares held | 6/17/2026 | View profile |
| Kenneth Bate Director | ▼ Sell | Open Market | 2,627 Shares held | 11/5/2025 | View profile |
| Rita Thakkar Chief Accounting Officer | ▲ Buy | Grant | 2,398 Shares held | 1/15/2026 | View profile |
| Jacqualyn A. Fouse Chief Executive Officer | ▲ Buy | Grant | 1,551 Shares held | 6/17/2026 | View profile |
| Daniel J. Brennan Director | ▲ Buy | Grant | 1,371 Shares held | 6/17/2026 | View profile |
| BAY CITY CAPITAL LLC 10% Owner | ▼ Sell | Other | 1,261 Shares held | 12/3/2021 | View profile |
| John C. Reed Director | ▲ Buy | Grant | 647 Shares held | 8/15/2026 | View profile |
Transaction History
| William John Sibold | ▼ Sell | Open Market | 160 | $86K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 687 | $371K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 368 | $199K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 60 | $32K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 106 | $57K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 218 | $117K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 1,202 | $652K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 1,539 | $837K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 761 | $415K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 120 | $66K | 9/11/2026 |
| William John Sibold | ▼ Sell | Open Market | 131 | $69K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 347 | $184K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 522 | $277K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 368 | $196K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 512 | $273K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 396 | $212K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 644 | $345K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 1,040 | $558K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 640 | $344K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 520 | $280K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 215 | $116K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 362 | $196K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 160 | $87K | 9/9/2026 |
| William John Sibold | ▼ Sell | Open Market | 505 | $273K | 9/9/2026 |
| Shannon T. Kelley | ▼ Sell | Open Market | 664 | $342K | 8/17/2026 |
| John C. Reed | ▲ Buy | Grant | 647 | $0 | 8/15/2026 |
| William John Sibold | ▼ Sell | Open Market | 280 | $155K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 140 | $76K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 110 | $60K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 545 | $297K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 275 | $150K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 269 | $147K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 680 | $372K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 47 | $26K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 153 | $84K | 7/20/2026 |
| William John Sibold | ▼ Sell | Open Market | 1 | $551 | 7/20/2026 |
| William John Sibold | ▲ Buy | Option Exercise | 50,000 | — | 7/17/2026 |
| Rebecca Taub | ▲ Buy | Grant | 454 | $0 | 6/17/2026 |
| Richard S. Levy | ▲ Buy | Grant | 454 | $0 | 6/17/2026 |
| Jacqualyn A. Fouse | ▲ Buy | Grant | 454 | $0 | 6/17/2026 |
| James M. Daly | ▲ Buy | Grant | 454 | $0 | 6/17/2026 |
| Daniel J. Brennan | ▲ Buy | Grant | 404 | $0 | 6/17/2026 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Grant | 908 | $0 | 6/17/2026 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Grant | 908 | $0 | 6/17/2026 |
| David Soergel | ▼ Sell | Open Market | 1,042 | $517K | 6/1/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 40 | $20K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 320 | $163K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 151 | $77K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 610 | $312K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 439 | $225K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 40 | $21K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 343 | $177K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 657 | $339K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 723 | $374K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 1,497 | $775K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 782 | $406K | 5/22/2026 |
| Richard S. Levy | ▼ Sell | Open Market | 80 | $42K | 5/22/2026 |
| David Soergel | ▼ Sell | Open Market | 844 | $435K | 5/18/2026 |
| Mardi Dier | ▼ Sell | Open Market | 646 | $279K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 40 | $17K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 420 | $179K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 80 | $34K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 160 | $69K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 40 | $17K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 120 | $52K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 116 | $50K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 160 | $69K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 80 | $35K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 80 | $35K | 3/6/2026 |
| Mardi Dier | ▼ Sell | Open Market | 40 | $18K | 3/6/2026 |
| William John Sibold | ▼ Sell | Open Market | 1,663 | $718K | 3/6/2026 |
| Shannon T. Kelley | ▼ Sell | Open Market | 360 | $155K | 3/6/2026 |
| Carole Huntsman | ▼ Sell | Open Market | 419 | $181K | 3/6/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 491 | $212K | 3/6/2026 |
| David Soergel | ▲ Buy | Grant | 4,374 | $0 | 3/4/2026 |
| Mardi Dier | ▲ Buy | Grant | 5,215 | $0 | 3/4/2026 |
| William John Sibold | ▲ Buy | Grant | 14,995 | $0 | 3/4/2026 |
| Shannon T. Kelley | ▲ Buy | Grant | 4,017 | $0 | 3/4/2026 |
| Carole Huntsman | ▲ Buy | Grant | 3,989 | $0 | 3/4/2026 |
| Mardi Dier | ▼ Sell | Open Market | 1,183 | $505K | 3/2/2026 |
| Richard S. Levy | ▲ Buy | Option Exercise | 2,500 | $18K | 2/23/2026 |
| Richard S. Levy | ▲ Buy | Option Exercise | 4,000 | $66K | 1/26/2026 |
| Carole Huntsman | ▼ Sell | Open Market | 340 | $167K | 1/26/2026 |
| Carole Huntsman | ▼ Sell | Open Market | 570 | $282K | 1/26/2026 |
| William John Sibold | ▼ Sell | Open Market | 1,577 | $777K | 1/26/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 647 | $319K | 1/26/2026 |
| Shannon T. Kelley | ▼ Sell | Open Market | 263 | $129K | 1/20/2026 |
| Shannon T. Kelley | ▼ Sell | Open Market | 429 | $215K | 1/20/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 2,238 | $1.1M | 1/20/2026 |
| Rita Thakkar | ▲ Buy | Grant | 2,398 | $0 | 1/15/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 691 | $366K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 280 | $149K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 80 | $43K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 332 | $177K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 148 | $79K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 473 | $254K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 487 | $261K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,480 | $758K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,094 | $561K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,345 | $692K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,996 | $1.0M | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 766 | $396K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 2,450 | $1.3M | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,363 | $707K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 846 | $440K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 681 | $355K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 840 | $438K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 970 | $507K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,199 | $628K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 2,432 | $1.3M | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,066 | $561K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,560 | $822K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 575 | $304K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 80 | $43K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 480 | $259K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 600 | $324K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 40 | $22K | 1/9/2026 |
| Rebecca Taub | ▲ Buy | Option Exercise | 240 | $4K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 40 | $22K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 200 | $110K | 1/9/2026 |
| Rebecca Taub | ▲ Buy | Option Exercise | 18,410 | $291K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 960 | $492K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 960 | $493K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 937 | $482K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 1,578 | $814K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 521 | $269K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 2,044 | $1.1M | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 970 | $503K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 539 | $280K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 440 | $229K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 588 | $307K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 732 | $383K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 465 | $246K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 554 | $293K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 256 | $136K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 30 | $16K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 40 | $21K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 271 | $145K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 89 | $48K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 299 | $160K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 385 | $207K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 40 | $22K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 400 | $216K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 40 | $22K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 400 | $217K | 1/9/2026 |
| Paul A. Friedman | ▲ Buy | Option Exercise | 280 | $4K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 280 | $154K | 1/9/2026 |
| Paul A. Friedman | ▲ Buy | Option Exercise | 24,520 | $387K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 1,335 | $700K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 1,489 | $782K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 913 | $480K | 1/9/2026 |
| Rebecca Taub | ▼ Sell | Open Market | 1,135 | $598K | 1/9/2026 |
| Paul A. Friedman | ▼ Sell | Open Market | 166 | $88K | 1/9/2026 |
| Paul A. Friedman | ▲ Buy | Option Exercise | 24,800 | $392K | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 624 | $342K | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 535 | $293K | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 409 | $225K | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 4,316 | $2.4M | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 7,193 | $4.0M | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 5,533 | $3.1M | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 5,001 | $2.8M | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 1,029 | $571K | 12/10/2025 |
| Paul A. Friedman | ▼ Sell | Open Market | 160 | $89K | 12/10/2025 |
| Rebecca Taub | ▲ Buy | Option Exercise | 18,650 | $295K | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 491 | $269K | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 369 | $202K | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 486 | $267K | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 4,723 | $2.6M | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 4,410 | $2.4M | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 3,857 | $2.1M | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 3,087 | $1.7M | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 1,027 | $570K | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Open Market | 200 | $111K | 12/10/2025 |
| Rebecca Taub | ▼ Sell | Gift | 5,455 | $0 | 12/10/2025 |
| William John Sibold | ▼ Sell | Open Market | 2,400 | $1.4M | 12/4/2025 |
| William John Sibold | ▲ Buy | Option Exercise | 50,000 | — | 12/3/2025 |
| Mardi Dier | ▼ Sell | Open Market | 160 | $94K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 160 | $94K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 74 | $44K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 80 | $48K | 12/2/2025 |
| Mardi Dier | ▲ Buy | Option Exercise | 4,173 | $1.1M | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 320 | $183K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 410 | $235K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 354 | $203K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 717 | $412K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 120 | $69K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 240 | $138K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 320 | $185K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 258 | $149K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 480 | $278K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 240 | $141K | 12/2/2025 |
| Mardi Dier | ▼ Sell | Open Market | 240 | $141K | 12/2/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 144 | $79K | 11/21/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 120 | $66K | 11/21/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 894 | $493K | 11/21/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 40 | $22K | 11/21/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 200 | $110K | 11/21/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 40 | $22K | 11/21/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 120 | $67K | 11/21/2025 |
| Carole Huntsman | ▼ Sell | Open Market | 200 | $112K | 11/21/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data
Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.